Female benign breast disease: papillary apocrine hyperplasia
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
- Daiichi Sankyo/AstraZeneca’s Enhertu Shows Positive Results in Phase III DESTINY-Breast06 Clinical Trial
- Mn007 Molecules Offer Potential for Combating Streptococcus pyogenes Infection
- Popular Indian Spices Banned in Hong Kong Over Carcinogen Concerns
Female benign breast disease: papillary apocrine hyperplasia
Female benign breast disease: papillary apocrine hyperplasia. Papillary apocrine hyperplasia does not increase the risk of breast cancer. In rare cases, these changes may occur with breast cancer.
Papillary apocrine hyperplasia is a rare disease that involves cells inside the ducts (epithelium) of the breast. There is a type of overgrown cell with the characteristics of “apocrine”, which means that the gel-like substance (called cytoplasm) that fills the cell is granular.
Papillary apocrine hyperplasia does not increase the risk of breast cancer. In rare cases, these changes may occur with breast cancer. They may also occur with other benign diseases that may increase the risk of breast cancer in the future, such as radial scars and atypical hyperplasia. However, the self-discovered changes in the papillary apocrine glands do not pose any additional risks.
If you are diagnosed with papillary apocrine changes, make sure that the pathologist (the doctor who checks the cell sample for diagnosis) can rule out any possibility of cancer. As the changes in apocrine glands are difficult to classify, it is recommended to seek consultation with another pathologist and give a second opinion.
(source:internet, reference only)
Disclaimer of medicaltrend.org